Why PG, JNJ, and KO Could Be 2027's Surprise Defensive Winners

Why this defensive trio still looks timely

This is still a quality insurance trade, but the chance to buy it at a clear discount may be narrowing. J&J raised its 2026 outlook last month, Coke just upgraded its full-year earnings and organic revenue outlook after a strong Q2, and PG is coming off a Q4 organic sales were flat while still promising progress across key measures in fiscal 2027. If those signals hold, waiting for even clearer defensiveness could mean paying a richer price later.

What investors are really buying

• Why now: The catalyst chain is already moving. J&J and KO are demonstrating resilience, while PG offers a reset setup if execution keeps improving.
• The tension: These are not bargain-bin names, and KO has climbed more than 19% this year. This is less about deep value than durable quality.
• The upside driver: Not heroic growth, but stability, pricing power, and regained investor confidence.

If management teams keep backing demand and guidance from a shaky backdrop, these names can still move from defensive holding to rerating candidate.

PG: the market is still fixated on the wrong line item

PG is the only name in this group still being judged mainly on headline demand. After a recent quarter where EPS topped estimates but revenue missed, the stock sold off more than 3% in premarket trading. The bigger question is whether investors will keep penalizing PG for top-line hesitation, or start noticing whether foundation building is beginning to translate into steadier growth.

Q4 obscured more than it revealed

The full-year picture was firmer than the post-earnings reaction suggested. Fiscal 2026 ended with net sales up 3%, organic sales up 1%, and diluted EPS up 2%. The pain came from Q4, when organic sales were flat and diluted EPS fell 15%. In a market with little patience for growth slippage, that one quarter overshadowed a still-resilient franchise.

Cash generation matters here. A defensive rerating does not require explosive revenue growth; it requires proof that pricing, mix, and cash conversion can continue funding dividends, buybacks, and innovation while the topline stabilizes. In Q3, PG reported net sales up 7%, organic sales up 3%, and diluted EPS up 6%.

The trigger that could re-rate PG

Management says it expects progress on each of its key measures in fiscal 2027. The market does not need perfection to respond. It needs consistency. If PG can show back-to-back quarters where organic sales move from flat to positive, investors may start rewarding clarity before they reward spectacular numbers.

Watch this: - Q3 already showed organic sales up 3%. - Q4 had shown organic sales were flat. - The next few quarters need to show that positive trend holding, alongside continued sales and earnings progress.

J&J and KO are already showing momentum; durability is the test

If PG still has trust to rebuild, J&J and Coke are past the first-impression phase. Their near-term job is simpler: show the improvement is durable enough to justify a higher multiple. That is the key split in this trade. J&J is the guidance-revision setup. KO is the momentum-beats-expectations setup. PG is the reputation-repair setup.

J&J's upside depends on whether the raised bar sticks

Johnson & Johnson already forced investors to reset expectations. In Q2, it delivered reported sales growth of 6.6% to $25.3 Billion, adjusted EPS of $2.90, and raised 2026 guidance to estimated reported sales of $101.1 Billion and adjusted EPS of $11.68. That goes beyond simple safe-haven appeal; it suggests a scaled healthcare business can still expand from within.

What matters next is follow-through. The bullish case strengthens if future quarters support the new midpoint.

Watch this: - Bullish durability: another quarter that supports 7.3% reported sales growth and 8.2% adjusted EPS guidance. - Invalidation: growth slips and the market starts treating the raised guidance as temporary.

Coke is showing real volume strength

Coca-Cola's setup is different because the momentum is already visible in both volume and guidance. Q1 showed organic revenues grew 10% with global unit case volume up 3%. Q2 followed with organic revenue grew 6%, global unit case volume up 5%, and Coca-Cola Zero Sugar volume up 16%. Once volume starts moving, investors are less likely to dismiss results as merely a pricing story.

The second-quarter report also strengthened the full-year case. Coke raised its full-year earnings and organic revenue outlook to comparable EPS growth of 9% to 10% and about 5% organic revenue growth. There was also some headline noise from Fairlife, but management said the stoppage was not expected to have a material impact.

Watch this: - Bullish durability: volume and organic revenue keep supporting the raised outlook. - Invalidation: growth falls back to price-only support.

The order of catalysts matters more than the brand halo

The setup is simple: watch execution, not reputation.

Timing rank

• KO first. The next earnings print is expected Tuesday before the bell, and the latest proof point is already there: global unit case volume grew 5% with organic revenue up 6%.
• J&J next. Management already showed it can change the story quickly by raising 2026 guidance. The next test is whether those higher expectations hold.
• PG last to convince, but potentially first to rerate. It still carries the most friction after Q4 organic sales were flat and diluted EPS fell 15%. But that is also why it could reprice fastest if the next few quarters confirm better execution.

What matters most over the next few quarters

• KO: repeat the volume-and-organic-revenue strength and show recent noise stays immaterial.
• J&J: defend the raised 2026 guidance with another quarter of solid operating momentum.
• PG: break the flat-organic, softer-EPS cycle and show the recovery trend is real rather than incidental.

Investors do not need heroic growth here. They need three defensive franchises to keep clearing a modest but meaningful bar. In this market, steady execution against mediocre expectations is often enough to force a rerating.